ArticleMaterials today. Bio2025
Co-assembly of natural small molecules into a carrier-free hydrogel with enhanced synergism for pancreatic cancer theranostic amplification.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nucleoside drives the self-assembly and enables delivery of phosphate containing therapeutics.Materials today. Bio · 2026Article
- Carrier-Free Supramolecular Hydrogel Self-Assembled from Triterpenoid Saponins from Traditional Chinese Medicine: Preparation, Characterization, and Evaluation of Anti-Inflammatory Activity.Gels (Basel, Switzerland) · 2026Article
- Biomaterials in pancreatic surgery: progress and challenges in preoperative, intraoperative and postoperative care.Theranostics · 2026Review
- Recent advances in hydrogel-based delivery systems for the treatment of pancreatic cancer.Materials today. Bio · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the most devastating solid tumors and lacks ideal therapeutic options. The efficiency of using classic chemotherapeutic agents like gemcitabine (GEM) solely has been limited immensely owing to severe resistance and systemic toxicity, thus necessitating alternative multi-pronged strategies. Multicomponent supramolecular co-assembly leveraging natural small molecules (NSMs) cannot only produce carrier-free hydrogel materials having superior mechanical properties for convenient administration, but also achieve optimal synergies in combinational drugs therapy. Herein, a natural structural analog of GEM with favorable pro-apoptotic effect, adenosine (Ado), was found firstly to self-assemble spontaneously into a hydrogel (Ado-gel). Sequentially, we constructed a novel two-component hydrogel (DA-gel) via co-assembling Ado with another NSM evidenced here as new autophagy inhibitor, gentisic acid (2,5-dihydroxybenzoic acid, DHB). Addition of DHB had reinforced the thermal-responsiveness and viscoelasticity evidently in DA-gel, which ascribed to the heightened intermolecular hydrogen bonding and π-π stacking interactions. Together with its good injectability and biosafety, the local injection can be conducted smoothly so as to improve the compliableness of patients in clinical settings. More intriguingly, DA-gel was proven to exhibit the best anti-tumor efficiency in pancreatic carcinoma comparing with corresponding single-component and mixture
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.